Calcium Acetate

Evidence Level: L5

Predicted Indications: 2

Calcium Acetate

Pharmacist Assessment Report

Calcium acetate: calcium-containing phosphate binder → calcium-alkali syndrome

One-Sentence Summary

Calcium acetate is a calcium-containing phosphate binder that lowers dietary phosphate absorption. The TxGNN model predicts it may be relevant to calcium-alkali syndrome, but this is a model prediction only: 0 clinical trials and 0 publications support it in the data compiled for this report. Because calcium acetate supplies calcium, it could plausibly contribute to this condition rather than treat it, so the prediction should be read as a possible safety signal.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	calcium-alkali syndrome
TxGNN Prediction Score	0.9990
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data
Number of Listed Products	4 (valid: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, calcium acetate is a calcium salt that binds phosphate in the gut and is used to lower phosphate in kidney disease.

Calcium-alkali (milk-alkali) syndrome is caused by excess calcium intake, usually together with absorbable alkali. It leads to high blood calcium, metabolic alkalosis and acute kidney injury. Since calcium acetate delivers a calcium load, the biological link points toward causing or worsening the condition, not treating it.

The very high score likely reflects the model’s closeness between related terms (calcium excess, phosphate metabolism, kidney calcification) rather than a true therapeutic relationship. No study in the data compiled for this report examines this disease directly, so the prediction has no experimental support.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
87055	Foswin Tablet	Strip of 10 tablets	Not recorded
247046	Zerofos DS Tablet	Strip of 10 tablets	Not recorded
203034	Specium Tablet	Strip of 10 tablets	Not recorded
175196	Phosnier 667 Tablet	Strip of 10 tablets	Not recorded

All four licences are valid single-ingredient oral products.

Safety Considerations

Drug Interactions: 83 interactions are recorded. Major interactions include:
- Dolutegravir
- Bictegravir
Moderate interactions include:
- Tetracycline-class antibiotics (doxycycline, tetracycline)
- Fluoroquinolones (gemifloxacin)
- Bisphosphonates (alendronic acid, risedronic acid, ibandronate)
- Calcium channel blockers (nifedipine, amlodipine)
- Beta-blockers (acebutolol, atenolol, betaxolol, bisoprolol)
- Thiazide diuretics (hydrochlorothiazide, bendroflumethiazide, benzthiazide)
- Topical vitamin D analogues (calcipotriol, calcitriol)
- Baloxavir marboxil

Package insert warnings and contraindications are not available in the data compiled for this report. Please refer to the package insert for these.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the model score. There are no trials or publications on this disease, and the biology suggests calcium acetate may contribute to calcium-alkali syndrome rather than treat it. This looks like a safety signal, not a repurposing opportunity.

To proceed, the following is needed:

Package insert warnings and contraindications from the licence holders
Mechanism of action data
Expert review of whether the prediction reflects a true therapeutic link or only a safety association
Any clinical or preclinical study that directly examines calcium-alkali syndrome
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.